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Abstract: Although COVID-19 affects mainly lungs with a hyperactive and imbalanced immune response, gastrointestinal and
neurological symptoms such as diarrhea and neuropathic pains have been described as well in patients with COVID-19. Studies indicate
that gut–lung axis maintains host homeostasis and disease development with the association of immune system, and gut microbiota is
involved in the COVID-19 severity in patients with extrapulmonary conditions. Gut microbiota dysbiosis impairs the gut permeability
resulting in translocation of gut microbes and their metabolites into the circulatory system and induce systemic inflammation which,
in turn, can affect distal organs such as the brain. Moreover, gut microbiota maintains the availability of tryptophan for kynurenine
pathway, which is important for both central nervous and gastrointestinal system in regulating inflammation. SARS-CoV-2 infection
disturbs the gut microbiota and leads to immune dysfunction with generalized inflammation. It has been known that cytokines
and microbial products crossing the blood-brain barrier induce the neuroinflammation, which contributes to the pathophysiology
of neurodegenerative diseases including neuropathies. Therefore, we believe that both gut–lung and gut–brain axes are involved in
COVID-19 severity and extrapulmonary complications. Furthermore, gut microbial dysbiosis could be the reason of the neurologic
complications seen in severe COVID-19 patients with the association of dysbiosis-related neuroinflammation. This review will provide
valuable insights into the role of gut microbiota dysbiosis and dysbiosis-related inflammation on the neuropathy in COVID-19 patients
and the disease severity.
Key words: COVID-19, gut microbiota dysbiosis, neuropathy, inflammation, gut–lung axis, gut–brain axis

1. Introduction
Over a hundred million people around the world have been
affected by the recent outbreak of the novel coronavirus
(SARS-CoV-2), COVID-191. Some of the individuals
infected with SARS-CoV-2 either remain asymptomatic
or have mild symptoms while some of them are admitted
to intensive care unit (ICU) with severe symptoms and
develop severe acute respiratory distress syndrome
(ARDS) (Chen et al., 2020b). SARS-CoV-2 infection
accompanied by multiple organ failure syndrome mostly
results in death due to damage in vital organs (Farooqui,
2021). SARS-CoV-2 has known to affect mainly the
respiratory system or lungs; nonetheless, symptoms
associated with gastrointestinal (GI) system have been
described as well in the patients with COVID-19. Fever,
cough, sore throat, dyspnea, and fatigue have been
reported as the most prevalent clinical symptoms. Over the
past year, GI symptoms emerged as critical manifestations
(Schmulson et al., 2021). Vomiting, nausea, and diarrhea
Worldometers (2021). Coronavirus cases [online]. Website https://
www.worldometers.info/coronavirus [accessed 20 May 2021].
1

have been described as the most prominent GI symptoms
in COVID-19. Frequency of GI symptoms in COVID-19
patients ranges from 5% to 80% with diarrhea ranging
from 2% to 50% (Chen et al., 2020a, 2020b; Fortune and
Sharaiha, 2020). Interestingly, GI manifestations have been
reported as the first symptoms in some cases occurring
even before the respiratory symptoms or fever (Song et
al., 2020; Lin et al., 2020). It is well established that the
digestive system contributes to the COVID-19 illness and
gastrointestinal signs at the beginning or during the course
of the disease should not be underestimated (Ferreira et
al., 2020; Jin et al., 2020; Tao et al., 2020; Wan et al., 2020).
While some of the patients display only the GI symptoms,
some with GI symptoms, in particular diarrhea, developed
severe respiratory complications requiring ventilation
support in ICU admission more often relative to those
with no GI symptoms (Jin et al., 2020; Pan et al., 2020; Wan
et al., 2020).
Zhang et al. (2021) performed a retrospective study
with 409 severe and hospitalized COVID-19 patients
and compared inflammatory markers of the patients
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with diarrhea to those without diarrhea to understand
the relationship between gastrointestinal symptoms and
immune response in COVID-19 patients. Patients with
diarrhea showed a low level of lymphocyte with reduced
CD8+ T cells and highly increased tumor necrosis factoralpha (TNF-α), interleukin-10 (IL-10), and IL-6 levels.
The severity of diarrhea with high frequency and long
duration was correlated with the inflammatory profile and
duration of the course of COVID-19. Moreover, diarrhea
was reported more often and more severe among patients
who died relative to those survived. Patients with diarrhea
tended to develop multiple organ failure and stay in
hospital longer. SARS-CoV-2 infection causes lung injury
resulting in pneumonia with a hyperactive and imbalanced
immune response (Li et al., 2020). Lymphocytopenia
and raised level of proinflammatory cytokines and
chemokines leading to “cytokine storm” have found to be
associated with severe COVID-19 accompanied by severe
acute respiratory syndrome in lung and multiple organ
dysfunction (Huang et al., 2020; Kalantar-Zadeh et al.,
2020; Zheng et al., 2020).
ARDS and sepsis-induced hypoxic damage, one of the
factors causing oxidative stress, lead to neurodegenerative
disorders and are associated with structural changes in
the brain of the patients with COVID-19 (Dolatshahi et
al., 2021). In a large-scale observational study comprising
214 individuals with COVID-19, the ratio of the patients
who declared neurologic complaints was about 36%
(Mao et al., 2020). Neurologic symptoms reported in
COVID-19 patients included headache, vertigo, altered
consciousness, encephalitis, neuropathic pain, facial
paralysis and olfactory disturbances, loss in sense of taste,
cerebrovascular events, and seizure (Bureau et al., 2020;
Mao et al., 2020). Although the mechanisms of neurologic
damage were unclear in the COVID-19 patients, sepsis,
systemic inflammatory response syndrome, and possible
SARS-CoV-2 interaction with the angiotensin-converting
enzyme 2 (ACE2) receptors in nerves, muscle, and brain
were considered to discuss their involvement in the
mechanism of action (Mao et al., 2020). Upregulation of
the proinflammatory cytokines such as IL-6, IL-8, and
TNF-α in COVID-19 patients, particularly in those with
more severe disease, raises doubts whether the cause of
the severe meningoencephalitis or/and other neurologic
manifestations in COVID-19 patients is the peripheral
inflammation rather than direct SARS-CoV-2 invasion
(Benameur et al., 2020; Dolatshahi et al., 2021). Peripheral
cytokines at increased level can cross the blood-brain
barrier directly and trigger neuroinflammation, which
contributes to the pathophysiology of neurodegenerative
diseases including neuropathies (Costello and Dalakas,
2020; Dolatshahi et al., 2021). Genetic predispositions,
metabolic risk factors, and dysbiosis in gut microbiota,
which are common risk factors for neurodegenerative

diseases and COVID-19, are thought to be partly
responsible for a higher incidence of neurodegenerative
diseases in COVID-19 survivors (Dolatshahi et al., 2021).
Since impaired intestinal microbiota decreases the gut
epithelial integrity and activate the immune system by
molecular mimicry and oxidative stress, gut microbial
dysbiosis involves the viral invasion directly into the central
nervous system (CNS) as well as the neurodegenerative
processes by changing neurotransmission balance.
Gut microbiota communicates with the brain, which
is called the gut–brain axis, maintaining homeostasis of
the gastrointestinal and the nervous system (Rhee et al.,
2009). SARS-CoV-2 affects brain functions most likely
through the gut–brain axis associated with dysbiosis and
inflammation. Alteration of the microbial composition
and its metabolites in the gut is associated with intestinal
permeability and systemic immune responses with
proinflammatory mediators which may lead to peripheral
sensitization of chronic pain in COVID-19 patients
(Leclercq et al., 2014; Thevaranjan et al., 2017). Therefore,
emerging role of gut microbiota in neuropathic symptoms
described by COVID-19 has attracted attention recently.
This review highlights the role of the gut microbial
dysbiosis on neuropathy in COVID-19 with association of
dysbiosis-related inflammation.
2. Gut microbiota in COVID-19 with the impact of
medication
Pathophysiology of the digestive manifestations in
COVID-19 has not been fully uncovered; however, it is
well known that there is a crosstalk between gut microbiota
and lung, and growing evidence draws attention to the
role of the gut microbiota in COVID-19 severity (Ferreira
et al., 2020; Wan et al., 2020; Tao et al., 2020). Microbial
populations in the gut contributes to health and influence
the homeostatic and physiological functions in humans
(Ostaff et al., 2013). While gut microbiota helps in
maturation and development of defense system in human
body, the immune system constructs the microbiota
composition and functions. It is well known that healthy
gut microbial composition is altered in various health
conditions such as inflammatory bowel disease, arthritis,
obesity, type 2 diabetes, and asthma (Aleman and
Valenzano 2019; Hufnagl et al., 2020; Tai et al., 2015).
Altered gut microbiota to an imbalanced state in healthy
individuals, dysbiosis, causes a disruption in balanced
immune functionality and a widespread inflammation.
When infants are exposed to antibiotics resulting in a
shift in the organization of the intestinal microbiota, in
the future, their risk of developing inflammatory bowel
disease increases due to the impact of gut microbiota
on immune development early in life (Shaw et al., 2010;
Hviid et al., 2011). Change in the gut microbiota alters the
intestinal barrier integrity with its immunomodulatory
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effect (Leclercq et al., 2014; Thevaranjan et al., 2017).
Raised level of inflammation in intestine due to dysbiosis
provokes epithelial barrier dysfunction, referred to as leaky
gut, and may lead to multiple organ failure with secondary
infection (Hanada et al., 2018; Fanos et al., 2020).
The gut–lung axis maintaining host homeostasis and
disease development with immunomodulation is thought
to be involved in disease severity and extrapulmonary
conditions of COVID-19 with the association of dysbiosis.
Damage in the intestinal barrier integrity due to dysbiosis
could result in SARS-CoV-2 translocation from lung to
gut lumen via circulatory and lymphatic system (Gu et al.,
2005; Aktas and Aslim 2020). Conversely, decrease in the
gut permeability due to dysbiosis could result in secondary
infection by intestinal microorganisms and leads to
multiple organ failure (Hanada et al., 2018; Deitch, 2012).
Considering the gut–lung crosstalk with the association of
gut permeability and systemic inflammation, individuals
with gut dysbiosis could be at high risk for severe
COVID-19.
Several studies have reported change in microbial
composition in feces from patients with COVID-19 (Table).
Overall, SARS-CoV-2 infection decreases the diversity and
increases the abundance of opportunistic pathogens in the
gut. COVID-19 patients from different studies varied in
their fecal microbial composition patterns (Table). This
variation could be due to life style with different dietary
habits among individuals or different treatment procedure
applied in different hospitals.
Dysbiosis involved in sepsis is one of the reasons for
the severity of SARS-CoV-2 infection with the association
of the gut–lung axis. Some of the patients with COVID-19
showing gastrointestinal symptoms, in particular diarrhea,
could have dysbiotic gut microbiota when they were
infected while for others who did not have dysbiotic
gut microbiota when infected, the treatment procedure
of COVID-19 might cause dysbiosis in their intestinal
microbiota. Antibiotics are primary disruptors of gut
microbiota breaking the balance between microbiota and
immune system and causing metabolic and immunologic
changes (Shaw et al., 2010; Hviid et al., 2011). Antibioticassociated diarrhea is one of the main side effects of
antibiotic administration due to the altered organization
of the intestinal microbiota (Hickson, 2011). Shift in the
gut microbial composition due to antibiotics increases the
risk of inflammatory disorders and new infections such as
Clostridium difficile infection which generates Clostridium
difficile-associated diarrhea (Shaw et al., 2010; Hickson,
2011; Hviid et al., 2011). Antibiotics have been commonly
used in COVID-19, particularly to prevent secondary
infection, and this extensive antibiotic administration
possibly has a role in disruption of the microbial balance
leading to diarrhea in COVID-19 patients (Chen et al.,
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2020b; Guan et al., 2020). The level of depletion in microbial
populations is much greater in antibiotic administered
patients with COVID-19 (Zuo et al., 2020; Cao et al.,
2021;Yeoh et al., 2021). Previously, dysbiosis in mice by
antibiotics were found to be associated with viral infections
in distal organs (Ichinohe et al., 2011). They reported that
antibiotics keep the commensal microbial populations in
the gut from regulating immune defense against influenza
A virus infection and mice had become more susceptible
to the virus infection in lungs. Although there has been no
effective treatment for COVID-19, a variety of treatment
regimens have been applied to the patients infected by
SARS-CoV-2 (Table). Gut microbiota can impact not only
the disease symptoms and the severity of the illness but
also the drug pharmacokinetics used to treat COVID-19
and patient response to the therapy applied (Noh et al.,
2017; Zhang et al., 2018; Zimmermann et al., 2019). When
the drug is metabolized by the gut microbiota before
absorption, bioavailability of the drugs could be altered
as well as the possible side effects. Hydroxychloroquine
(HCQ) is an antimalarial drug that has been used for
inflammatory disorders including rheumatoid arthritis for
years. After the outbreak, it was one of the earliest drugs
used for the prevention and treatment of COVID-19 due
to its in vitro antiviral effect against SARS- CoV-2 (Yao
et al., 2020). It has been demonstrated in mice that HCQ
challenge significantly changed the gut microbial diversity
with depletion in Firmicutes and increase in Bacteroidetes;
however, it did not impact the immune response (Pan
et al., 2021). While HCQ have been used alone in some
COVID-19 cases, it is sometimes used in combination with
azithromycin (Das et al., 2020). Due to adverse outcomes
of COVID-19, related to immune response with increased
proinflammatory cytokines resulting in cytokine storm,
antiinflammatory drugs such as corticosteroids have been
used as well (Felsenstein et al., 2020). Additionally, antiviral
drugs such as favipiravir, remdesivir, and ribavirin have
been commonly used for COVID-19 treatment. The list of
the drugs that have been tested as COVID-19 therapeutic
agent is much longer than those mentioned here. While
some of them are administered alone, some are used in
combination depending on the treatment regimen that
has been used in clinical practice in different hospitals
or different countries. However, in most of the studies,
either information about the treatment procedure is
limited or treatment regimen covers combination of two
or more drugs including HCQ, antiviral drugs, steroids,
and antibiotics and varies among patients involved in
the same study (Ceccarelli et al., 2021; Cao et al., 2021;
Livanos et al., 2021). Different therapeutic interventions
can influence the intestinal microbiota and eventually
impact the gastrointestinal manifestation in patients with
COVID-19 and the severity of the illness associated with
dysbiosis during the course of the disease.
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Table. Changes in the composition of fecal microbiome of COVID-19 patients.

Modulation of fecal microbiota

*Antibiotics

↑ Ruminococcus gnavus,
Eggerthella, Coprobacillus,
Lachnospiraceae bacterium, Clostridium
ramosum, and Eggerthella lenta
↓ Alistipes sp AP11, Roseburia
intestinalis, Burkholderiales bacterium,
Eubacterium hallii, Parasutterella
excrementihominis,
Alistipes indistinctus, Coprobacter
fastidiosus, Eubacterium eligens,
Bacteriodales bacterium ph8,
Bacteroides salyersiae, Odoribacter
splanchnicus, Alistipes shahii,
Ruminococcus bromii,
and Bacteroides massiliensis

*Antivirals or other
drugs

None,
moxifloxacin,
None, lopinavir/
piperacillin/
ritonavir, arbidol, or
tazobactam,
ribavirin
cefuroxime, or
levofloxacine

Geographic Gastrointestinal
References
location
symptoms

Beijing,
China

None, diarrhea,
constipation,
(Cao et al. 2021)
or abdominal
distention

Antibiotics
(unspecified)

Antivirals
(unspecified),
corticosteroids,
immunoglobulin,
Hefei,
traditional Chinese
China
medicine, probiotics,
anticoagulation, or
tocilizumab
(anti-IL6R)

Diarrhea,
nausea, vomit,
anorexia,
or abdominal
pain

(Tao et al. 2021)

Antibiotics
(unspecified)

Antifungal drugs or
probiotics

NA

NA

** (Tang et al. 2020)

NA

NA

Hong Kong, None or
China
diarrhea

*** (Zuo et al. 2021)

NA
↓ Ruminococcaceae,
Fusicatenibacter, Anaerostipes,
Agathobacter, unclassified
Lachnospiraceae, and Eubacterium hallii

NA

Zhejiang,
China

(S. Gu et al. 2020)

↑ Streptococcus, Clostridium,
Haemophilus, and Proteobacteria
↓ Prevotella, Akkermansia,
Paraprevotella, and Lachnospira

↑ Enterococcus and Enterobacteriaceae
↓ Lactobacillus, Bifidobacterium,
Faecalibacterium prausnitzii,
Clostridium butyricum, Clostridium
leptum, and Eubacterium rectale
↑ Collinsella aerofaciens, Collinsella
tanakaei, Streptococcus infantis,
and Morganella morganii
↓ Parabacteroides merdae,
Bacteroides stercoris, Alistipes
onderdonkii, and Lachnospiraceae
bacterium
↑ Streptococcus, Rothia, Veillonella,
Erysipelatoclostridium, and Actinomyces
None or
diarrhea
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Table. (Continued).

Modulation of fecal microbiota
↑ Ruminococcus gnavus,
Ruminococcus torques, and
Bacteroides dorei
↓ Bifidobacterium adolescentis,
Faecalibacterium prausnitzii, and
Eubacterium rectale
↑ Clostridium hathewayi, Actinomyces
viscosus, and Bacteroides nordii

*Antibiotics

*Antivirals or other
drugs

Geographic Gastrointestinal
References
location
symptoms

Antibiotics
(unspecified)

None, lopinavir/
ritonavir, ribavirin,
or oseltamivir.
Corticosteroids
or proton pump
inhibitor

Hong Kong, None or
China
diarrhea

(Yeoh et al. 2021)

Hong Kong, None or
China
diarrhea

(Zuo et al. 2020)

Anhui,
China

(Tao et al. 2020)

Amoxycillin,
Lopinavir/ritonavir,
clavulanate
or ribavirin.
cephalosporin,
↓ Eubacterium ventriosum,
Interferon beta-1b
Faecalibacterium prausnitzii, Roseburia, or tetracycline
and Lachnospiraceae.
↑ Streptococcus, Clostridium,
Lactobacillus, and Bifidobacterium
↓ Bacteroidetes, Roseburia,
Faecalibacterium, Coprococcus, and
Parabacteroides.

NA

NA

NA

*Single or combination of two or more. ** Predominant fecal microbiota was detected by qPCR. *** Change in the microbiota in fecal samples with
signature of high SARS-CoV-2 infectivity relative to the fecal samples with signature of low-to-none SARS- CoV-2 infectivity. NA, no information
available

3. Gut–brain axis in COVID-19
Alternatively, diarrhea or other gastrointestinal
manifestations could be the result of the gut-brain axis.
Physiological processes of functional gastrointestinal
disorders were found to be involved in dysregulation of
bidirectional gut–brain interaction in addition to dysbiosis
of the gut microbiota with inflammation and impaired
gut barrier (Black et al., 2020). Interactions between the
gut microbiota and the brain have been explored, and
the results indicate that intermediaries resulting from
the interaction between the gut immune system and
the microbiota may impact the brain functions (Mayer
et al., 2014; Shanahan and Quigley, 2014). Changes in
the bidirectional relationship between the gut and the
nervous system have been shown to play an important
role in irritable bowel syndrome (IBS) pathogenesis and
associated functional gastrointestinal disorders with GI
manifestations such as abdominal pain, diarrhea, or/and
constipation (Mari et al., 2020; Simpson et al., 2020; Holvoet
et al., 2021). It is interesting that germ-free animals have
been found to exaggerate the activation of hypothalamic–
pituitary–adrenal axis, a central stress response system, in
response to stress. This hyperresponsiveness was reversed
by restructuring the microbiota with fecal suspension
from animals kept in a pathogen-free environment or
through oral inoculation of B. infantis (Sudo et al., 2004;
Smith and Vale 2006). Although the exact mechanism is
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not known fully yet, gut microbiota is capable of impacting
stress and visceral hypersensitivity (Moloney et al., 2016).
Recent studies performed fecal microbiota transplantation
(FMT) from healthy donors to patients with IBS and
reported that modulation of the gut microbiota by
FMT relieved symptoms such as abdominal pain in IBS
patients compared to the control group (Johnsen et al.,
2018, 2020; El-Salhy et al., 2021; Holvoet et al., 2021). GI
microbiota is a critical piece with its potential to affect
neuro-immuno-endocrine pathways. The gut microbiota
and its metabolic products are capable of modifying GI
functions by impacting the gut barrier integrity, immune
function, enteric nervous system (ENS), and brain (Mayer
et al., 2014). Studies support that microbiota is involved
in adult neural plasticity including microglia activation
and neurogenesis and is necessary for normal brain
development and healthy brain functions in adulthood
(Hsiao et al., 2013; Ogbonnaya et al., 2015; Stilling et al.,
2015). Antibiotic-induced microbiota depletion in mice
affects cognitive behaviors and anxiety in addition to the
gut–brain axis neuromodulators including neuropeptides,
monoamines, and tryptophan (Desbonnet et al., 2015).
Conversely, the brain can modify the environment of the
gut microbiota through ENS, autonomic nervous system,
and hypothalamic pituitary axis by altering the luminal
secretion, epithelial integrity, mucosal immunity, and
release of neurotransmitters (Rhee et al., 2009; Mayer,
2011).
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Metabolites produced by gut microbiota such as
tryptophan, serotonin, GABA, and short chain fatty acids
and immune molecules generated during the immune
response against microbes can signal through the intestinal
cells and affect the gut locally. Moreover, these molecules
can signal through the endocrine and neurocrine system
associated cells and impact extraintestinal organs such
as the brain (Mayer et al., 2014). Short chain fatty acids
produced by intestinal microbiota play an important role
in maturation and activation of microglia cells which
are macrophage-like immune cells in the CNS (Lin et
al., 2020). Microbial products can translocate to the
circulatory system from the gut and reach the blood-brain
barrier. With the changes in the gut microbial composition,
increased intestinal permeability and activated immune
response may lead to systemic inflammation and impact
the blood-brain barrier, and eventually induce neural
injury and neurodegeneration with neuroinflammation
(Rhee et al., 2009; Heiss and Olofsson 2019). Furthermore,
gastrointestinal tract is the largest endocrine organ in
the human body and produce intestinal hormones via
the enteroendocrine system with a wide range of targets
both intestinal and extraintestinal (Ahlman and Nilsson,
2001). Intestinal hormones, such as neuropeptide Y,
glucagon-like peptide 1, and peptide YY, produced by
enteroendocrine cells play a role in pain modulation with
the association of the immune and nervous systems. It
has been shown that gut microbiota communicates these
enteroendocrine cells and impact the enteroendocrine
metabolism. SARS‐CoV‐2 infection is thought to result in
symptoms of vomiting or nausea through either inducing
enteroendocrine release in the gut mucosa or impacting
the brainstem directly after getting into the circulatory
system (Andrews et al., 2021).
4. Gut microbiota and inflammation associated
neuropathy in COVID-19
Although SARS-CoV-2 mainly infects the respiratory
system, nervous system has been found to be involved
in COVID-19 as well, with neurological symptoms
including anosmia, headache, anorexia, vertigo, altered
consciousness, encephalitis, neuropathic pain, facial
paralysis and olfactory disturbances, and loss in sense
of taste (Bureau et al., 2020; Mao et al., 2020; Wu et al.,
2020). SARS-CoV-2 recognizes the ACE2 receptor and
invades the host cell via type II transmembrane serine
protease (TMPRSS2) (Zhang et al., 2020). Since the ACE2
receptor and the TMPRSS2 are expressed at relatively low
levels in the brain, it is hard to state for now that SARSCoV-2 directly invades the CNS and causes neurological
damage. It has been thought that the gut–brain axis may be
involved in COVID-19, and SARS-CoV-2 might affect the
CNS via intestine associated inflammation (Shi et al., 2020;
Wu et al., 2020). Coronaviruses damage the structure and

function of the nervous system with their ability of entering
the cerebrospinal fluid (Marasco et al., 2021). Although the
mechanism(s) by which SARS-CoV-2 reaches the central
nervous system is essentially unknown, it is believed that
the blood-brain barrier is involved in the invasion path
(Marasco et al., 2021). Previously, neurotropic viruses
were shown to infect the ENS continuously and cause GI
dysfunction (Brun et al., 2010).
Decrease in gut barrier function with the change in
the gut microbiota due to viral infection will modify the
blood-brain barrier integrity and let bacteria, bacterial
metabolites, and toxins translocate to the brain via systemic
circulation, then will cause damage in brain functions
(Lin et al., 2020). Vagus nerve is linked to the neurons
in the ENS and carries information from the intestine to
the brain; therefore, ENS dysfunction can impact both
the gastrointestinal system and brain functionality via
gut-brain axis (Tognini, 2017). Recently, Deffner et al.
(2020) explored a histological evidence of alternative
routes for SARS-CoV-2 neuroinvasion and performed
immunostainings for ACE2 and TMPRSS2 in the human
ENS and choroid plexus. They reported that enteric
neurons and glial cells in the small and large intestine and
choroid plexus epithelium cells expressed both ACE2 and
TMPRSS2. Studies suggest that SARS-CoV-2 reaching the
gut directly or indirectly invades the ENS and travels to the
brain via vagus nerve to impact the central nervous system
(Jakhmola et al., 2020; Deffner et al., 2020). Moreover,
damage in the ENS could cause intestinal dysmotility and
disturbed barrier function which lead to translocation
of gut microbes and their metabolites into the systemic
circulation to the brain, suggesting the bidirectional
interaction between gut and the nervous system. On the
other hand, coronaviruses are thought to move to the brain
via motor or sensory nerve endings along with retrograde
neuronal transport through the motor proteins including
kinesin and dynein (Cataldi et al., 2020; Marasco et al.,
2021). Recently, ENS has been suggested to be the route
for SARS CoV-2 to enter the brain and the virus would
reach the brain through vagal and/or splanchnic nerves
(Esposito et al., 2020).
Severe SARS-CoV-2 infections have been found to be
associated with neuropsychological effects and COVID-19
patients have been diagnosed with neuropathic pain
including olfactory tract neuropathy, motor peripheral or
axonal neuropathy, and sensory neuropathy (Abdelnour et
al., 2020; Ghosh et al., 2020; Kirschenbaum et al., 2020; Li et
al., 2021; Odriozola et al., 2021). The somatosensory nerve
signals are sent to the brain from the spinal cord for further
processing the sense of temperature, pressure, pain, touch,
and vibration. Diseases impacting somatosensory nervous
system such as diabetes, infections, nerve trauma, and
autoimmune diseases can dysfunction the sensory signals
into the spinal cord and the brain and lead to disorders
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associated with neuropathic pain (Campbell and Meyer,
2006). Neuropathic pain impairing the quality of life in
patients reflects both central and peripheral sensitization
and immune mechanism is involved in this matter of
fact. Cooperation between the nervous system and the
immune system have emerged as key in pain development
(Ellis and Bennett, 2013). Proinflammatory cytokines
and chemokines such as IL-1β and TNF-α construct the
fundamental mechanism building the neuroimmune
communication and lead to hyperalgesia and allodynia
following nerve injury (Ellis and Bennett, 2013; Campbell
and Meyer, 2006). Inhibition of increased chemokines and
cytokines, and their receptors in central and peripheral
nervous systems notably alleviates neuropathic pain. As
mentioned earlier, the microbial composition plays a pivotal
role in modulation of the immune system development, in
addition to the pathogenesis of many inflammatory-related
diseases (Rooks and Garrett, 2016). Amaral et al. (2008)
explored the impact of microbiota on inflammatory pain
with germ-free and conventional mice exposed to various
inflammatory stimuli such as LPS, TNF-α, IL-1β, CXCL1,
PGE2, and carrageenan. Their results demonstrated that
commensal microbiota is required for mice to generate
inflammatory hypernociception.
The gut microbiota is implicated in maintaining the
function of the CNS via the immune system, endocrine
system, or nervous system (Tognini, 2017; Chen et al.,
2021). Previously, the contribution of the gut microbiota
to the pathogenesis of the neuropathic pain accompanying
cancer chemotherapy and inflammatory pain have been
shown in studies using antibiotic-treated mice and germfree mice (Amaral et al., 2008; Shen et al., 2017). Ding
et al. investigated whether gut microbiota impact the
neuropathic pain and if T-cell mediated immune responses
are involved in this process using a mouse model of
peripheral nerve injury-induced chronic neuropathic pain
(Ding et al., 2021). Their results demonstrated that changes
in the gut microbiota alter the development of neuropathic
pain via shaping the balance between proinflammatory and
antiinflammatory T cells. In another recent study using
the same neuropathic pain model in rats, the relationship
between the intestinal microbiota and related metabolites
in neuropathic pain was explored (Chen et al., 2021). Gut
microbiota, serum and spinal cord metabolomics, and
pain‑related parameters were compared to unravel their
relation to each other. They reported that changes in the gut
microbial composition was significantly correlated with
the changes in the level of serum metabolites indicating
that gut microbiota involved in modulating neuropathic
pain and related metabolites, especially metabolites
taking role in neuroinflammation signaling pathways,
including arachidonic acid, beta-hydroxy butyric acid,
3-methylhistidine, 2-hydroxybutanoic acid, N6,N6,N6-
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trimethyl-l-lysine, l-histidine, l-anserine, l-tyrosine,
dopamine, anthranilic acid, and kynurenic acid.
Neurotransmitters, which can be either inflammatory
or noninflammatory mediators, contribute to pain
perception. GABA and glutamate are neurotransmitters
commonly found in the body as inhibitory and excitatory
neurotransmitters, respectively (Strandwitz et al.,
2019). Both bacteria and host are capable of converting
glutamate to GABA associated with regulating level of
proinflammatory cytokines, modulating pain status, and
maintaining gastrointestinal tract innervation. Human
gut microbiota is predicted to comprise genera that are
able to produce or consume GABA such as Escherichia,
Bacteroides, and Parabacteroides species. GABA level has
been reported to be modulated by altering the intestinal
microbial composition, in particular Bacteroides which is
negatively correlated with the brain signatures linked to
depression (Strandwitz et al., 2019).
The interaction between the nervous system and the
immune system is bidirectional; the nervous system,
therefore, regulates innate and adaptive immunity and
vice versa (Pitocco et al., 2021). The autonomic nervous
system modulates the immune response via negative
feedback process after the inflammatory cells deliver the
sensory information. Once afferent neurons are activated,
inflammatory mediators such as TNF-α can reach the
CNS via circumventricular organs lacking blood-brain
barrier. SARS-CoV-2 infection damages lungs with a
hyperactive and imbalanced immune response (Li et
al., 2020). Increased number of the proinflammatory
cytokines in COVID-19 patients results in cytokine storm
which is associated with severe COVID-19 and multiple
organ dysfunction (Huang et al., 2020; Kalantar-Zadeh et
al., 2020; Zheng et al., 2020). The gut–lung axis maintains
host homeostasis and disease development with the
association of immune system. The communication of the
gut microbiota with immune system and lung influences
the COVID-19 severity in patients with extrapulmonary
conditions including neuropathy. SARS-CoV-2 infection
may disturb the healthy intestinal microbiota and cause
immune dysfunction and generalized inflammation
(Aktas and Aslim, 2020). This dysbiosis may impair
the gut permeability resulting in secondary infection
with increased inflammation and affect distal organs via
circulatory and lymphatic system.
Moreover, gut microbiota plays a role in managing the
tryptophan availability for kynurenine pathway involved
in both central nervous and gastrointestinal system for
inflammation regulation (Follmer, 2020; Zhang et al., 2021).
Inflammation and tryptophan along with kynurenine
pathway is thought to be linked to depression-like behavior
with the association of dysbiosis and gut permeability
(Leclercq et al., 2014). In addition, kynurenine was shown
to induce pain hypersensitivity (Huang et al., 2016).
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Tryptophan serves as a precursor molecule to serotonin,
kynurenine, and other downstream metabolites produced
in the kynurenine pathway, and changes in the tryptophan
availability can impact the ENS and CNS functionality in
the gut–brain axis (O’Mahony et al., 2015; Kennedy et al.,
2017). Inflammatory cytokines can induce the expression
of the enzyme, indoleamine-2,3-dioxygenase (IDO), being
involved in tryptophan catabolism through the kynurenine
pathway and regulating hyperinflammatory responses
(O’Mahony et al., 2015; Xiao et al., 2021). Tryptophan
metabolism was shown to be altered in COVID-19 patients
with an increased kynurenine:tryptophan ratio suggesting
an elevated IDO activity (Shen et al., 2020; Thomas et al.,
2020; Ansone et al., 2021). Recently, Xiao et al. (2021)
studied integrated metabolites and cytokine analysis
in COVID-19 patients and reported that kynurenine
positively correlated with proinflammatory cytokines
while tryptophan negatively correlated with those.
Moreover, decrease in metabolites such as kynurenine
represented the alleviation of the hyperactivation of
tryptophan-kynurenine pathway. It has been demonstrated
that plasma tryptophan concentration was increased in
germ-free mice with decreased kynurenine:tryptophan
ratio and the tryptophan level was normalized with
colonization of the mice postweaning, suggesting the role
of gut microbiota on tryptophan metabolism (Clarke et
al., 2013). In another study feeding rats with Lactobacillus
johnsonii, they found that level of serum kynurenine was
significantly decreased in L. johnsonii fed rats compared
to the controls (Valladares et al., 2013). Furthermore,
plasma level of kynurenine was found to be increased in
the patients with IBS relative to the controls and the IBS
severity is correlated with kynurenine:tryptophan ratio
(Fitzgerald et al., 2008; Gerard Clarke et al., 2009, 2012).
These studies could indicate the possible link between
the tryptophan metabolism and the gut–brain axis. Gut
dysbiosis in COVID-19 patients may be the reason for the
dysfunction of the kynurenine pathway which has been
suggested to play an important role in oxidative stress
and neuroinflammation in neurodegenerative diseases
(Follmer, 2020). Significantly elevated levels of IL-6 and
TNF-α are correlated with COVID-19 severity, and the
concentration of IL-6 in COVID-19 patients is linked to
the tryptophan metabolism into the kynurenine pathway
(Zhang et al., 2021; Follmer, 2020). COVID-19 impairs the
healthy gut microbiota and leads to immune dysfunction
and generalized inflammation (Aktas and Aslim, 2020). A
high level of peripheral cytokines crossing the blood-brain
barrier induces the neuroinflammation which contributes
to the pathophysiology of neurodegenerative diseases
including neuropathies (Costello and Dalakas, 2020;
Dolatshahi et al., 2021). On the other hand, various tissues
and organs including respiratory and digestive tracts
express ACE2 receptors, and corrupted ACE2 expression

is thought to be related to viral infection, dysbiosis in gut
microbiota, and immune imbalance (Chhibber-Goel et al.,
2021). ACE2 was shown to maintain the neutral amino
acid (tryptophan) transporter B0AT1 in the gut and
coordinate antimicrobial peptides which helps gut stability
(Hashimoto et al., 2012). Diminished tryptophan level due
to impaired ACE2 expression fails to induce the secretion
of antimicrobial peptides which then leads to pathogen
survival and dysbiosis in the gut (Chhibber-Goel et al.,
2021; Rajput et al., 2021). Since this dysbiosis subsequently
results in susceptibility to the intestinal inflammation,
the COVID-19 patients with GI complications may have
increased respiratory distress relative to the patients with
no gut involvement (Chhibber-Goel et al., 2021; Rajput et
al., 2021; Zhang et al., 2021).
5. Gut microbiota targeted interventions in COVID-19
Taken together all these interactions between the gut
microbiota, the immune system, and the distal organs
including lung and brain, gut microbial dysbiosis could be
the reason of the neurologic complications seen in severe
COVID-19 patients with the association of dysbiosisrelated neuroinflammation. SARS-CoV-2 affects brain
functions most likely through the gut–brain axis and
induces neuropathy associated with dysbiosis-related
inflammation.
Targeted microbial alteration in the GI system could be
a strategy to attenuate the disease symptoms in COVID-19
patients. Fecal microbiota transplantation (FMT)
performed to treat patients with Clostridium difficile
infection is an excellent example of maintaining health
and disease through microbiota modification (Bakken et
al., 2011). FMT is an effective powerful way of modulating
the disrupted intestinal microbiota and improving
immunity and could be considered an alternative
approach to reduce neuropathy in COVID-19 patients
and the disease severity. Diabetic neuropathy is thought
to play a role in COVID-19 severity with dysfunction of
the autonomic nervous system determining the failure in
regulation of immune response and leading to decrease in
pulmonary function (Pitocco et al., 2021). FMT has been
promoted as an alternative strategy to relieve diabetic
neuropathy in a patient with history of diabetes and
hypertension for 8 years (Cai et al., 2018). Recently, FMT
procedure has been applied to improve chronic norovirus
infection in an immunosuppressed patient with kidney
transplant (Barberio et al., 2020). After 5 days of FMT,
the stool sample was negative for norovirus infection with
complete symptom resolution. FMT has been evaluated
as a potential strategy to manage viral hepatitis as well2
(Sehgal et al., 2020). There is one clinical trial published on
FMT application against COVID-19 with a few limitations
such as small sample size (Liu et al., 2021). The study
ClinicalTrials.gov. (2021). ClinicalTrials. https://clinicaltrials.gov/
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was performed on patients cured and discharged from
hospital instead of COVID-19 patients under treatment in
hospital and the trial was nonrandomized. They reported
that FMT restored the gut microbiota by increasing the
abundance of Faecalibacterium and Bifidobacterium.
Probiotics are another approach for targeted microbial
modulation in the gastrointestinal system that could help
with improving COVID-19 symptoms. Experimental
and clinical studies exploring the impact of probiotics on
respiratory system viruses, such as influenza, to improve
the severity of viral respiratory tract infections and to
decrease the risk of infection have been documented well
(Singh and Rao, 2021). Clinical trials2 all around the world
are ongoing to test the impact of probiotics on modulation
of the gut microbiota and the efficacy in patients with
COVID-19 patients with only two of them published
yet. In a trial comprising 70 individuals, SARS-CoV-2–
positive patients received either only the required drug
therapy or a commercial multistrain probiotic formulation
along with the drug therapy during hospitalization
(d’Ettorre et al., 2020). The probiotic supplementation
showed a reduction in the severity of COVID-19 patients
with improvement in diarrhea and other COVID-19–
associated symptoms within about 72 h. Moreover, risk
of developing respiratory failure and the ratio of the
patients moved to ICU were higher in the nonprobiotic
group relative to the probiotic group. Another trial with
the same probiotic formulation delivered to 200 patients
with severe COVID-19 pneumonia, the mortality rate,
the ICU hospitalization emergency, and the length of
hospitalization were evaluated (Ceccarelli et al., 2021). The
mortality rate was much higher in the nonprobiotic group
with 30% compared to the probiotic group with 11%.
6. Conclusion
It is well established that gut microbiota contributes to the
COVID-19 severity with the association of the gut–lung

axis (Ferreira et al., 2020; Jin et al., 2020; Wan et al., 2020;
Tao et al., 2020). Gut microbiota serves as an extra organ
and maintains physiological and homeostatic functions
by communicating distal organs with the association of
immunomodulation (Dachuan et al., 2019; Dapeng et
al., 2020). The gut–brain axis is another crosstalk that gut
microbiota is involved in COVID-19 manifestations and
severity of the disease. This axis is linked to various tissues
and organs, including immune cells, autonomic nervous
systems, glands, brain, and intestine, with its microbial
composition and communicates with each to preserve
homeostasis. Recent studies support that gut microbiota
plays a crucial role in neuropathic pain, abdominal pain,
headache, and inflammatory pain (Amaral et al., 2008;
Guo et al., 2019; Cuozzo et al., 2021). Dysbiosis of the gut
microbiota, either at the onset of SARS-CoV-2 infection
or during the course of the disease with drug treatment,
could be the reason for COVID-19 manifestations,
including neuropathic pain, abdominal pain, headache
and more. Although there has been no effective drug or
treatment for COVID-19, a variety of treatment regimens
have been applied to the patients infected by SARS-CoV-2.
Different therapeutic interventions can result in dysbiosis
and eventually impact the brain through the gut–brain
axis with drug-associated dysbiosis. Regardless of the
order of the incidents leading to dysbiosis in patients
with COVID-19, alteration in the gut microbiota tends
to influence the bidirectional relationship between the
gut and the brain. Considering the relationship between
the gut microbiota and the immune system influencing
the neuropathy in COVID-19 patients, rebuilding the
gut microbiota to maintain a healthy status could be
an alternative strategy to improve the neuropathy in
COVID-19 patients. Specific interventions such as live
biotherapeutics or microbiota-derived metabolites-based
approaches might be effective in COVID-19 patients for
dysbiosis-associated neuropathy.
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